Abiomed, Inc. announced multiple commercial and product-innovation milestones during the first quarter of fiscal 2021, despite the slowdown in sales caused by the pandemic.
“Our disciplined execution in Q1 delivered one of our most productive quarters in my 16-year tenure with the company,” Abiomed CEO Michael Minogue said during a 6 August conference call.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?